|
Compound class:
Synthetic organic
Comment: Losudesivir is the INN for an adenosine analogue that is intended as a coronavirus antiviral agent. The structure was obtained from WHO INN Proposed List 135 (July 2026). It represents an orally bioavailable RdRp inhibitor known by the codes SHEN26 and ATV014 that exhibits broad-spectrum activity against multiple coronaviruses [3-5]. Structurally, losudesivir is a cyclohexane carboxylate prodrug of the parent compound and active metabolite of remdesivir, GS-441524. Mechanistically RdRp inhibitors disrupt viral nucleic acid synthesis and thereby replication.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| SHEN26 was progressed as a clinical candidate for the treatment of COVID-19. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05504746 | A Phase I Study of SHEN26 Capsule in Healthy Participants | Phase 1 Interventional | Kexing Biopharm Co., Ltd. | 2 | |
| NCT05676073 | Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19 | Phase 2 Interventional | Kexing Biopharm Co., Ltd. | 1 | |